Study of the usefulness of neoadjuvant chemo-hormone therapy for high-risk prostate cancer

Study of the usefulness of neoadjuvant chemo-hormone therapy for high-risk prostate cancer - Neoadjuvant chemo-hormone therapy for high-risk prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030346

Enrollment

Registered

2017-12-11

Start date

2017-12-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Degaarelix and estramustine would be preoperatively administared for 3 months.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. After receiving sufficient explanation for the participation of this study, those who gained written consent by the with sufficient understanding 2. Men aged 20 or over,and under 80. 3. Patients diagnosed with high risk based on the D'Amico risk group classification.

Exclusion criteria

Exclusion criteria: 1. Patients who receiving hormonal therapy. 2. AST/ALT more than 100 IU/L by screening. 3. Patients who are judged inteligible for entry to this study principal investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
2Y Desease-Free Survival (PSA =>0.2ng/ml)	—

Secondary

Measure	Time frame
Perioperative complications	—

Countries

Japan

Contacts

Public ContactKosuke Fukaya

Fujita Health University Hospital urology

kofukaya@fujita-hu.ac.jp0562-93-9257

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026